GLP-1 Trends Infographic

Learn more about trends in GLP-1 perceptions and coverage strategies

Obesity is one of the largest public health concerns in the United States, and for many people, lifestyle modification alone does not produce sufficient weight loss. The GLP-1 drugs now used for treatment of obesity began as type 2 diabetes drugs. Given the high demand for GLP-1s and rapidly shifting environment with respect to these drugs, learning payers’ perspectives is critical.

In PSG’s 2024 Trends in Drug Benefit Design Report survey, we asked health plans and employers about their perspectives and strategies related to GLP-1s. Download the infographic to see key report statistics, including:

• 92% of plans cover GLP-1s for type 2 diabetes, while 36% cover GLP-1s for obesity
• 70% of respondents are moderately or very concerned about off-label use of GLP-1s for type 2 diabetes
• Among plans that cover GLP-1s for obesity, 81% use prior authorization and 58% have a BMI requirement
• The most commonly selected top reasons for excluding GLP-1s for obesity from coverage are that the drugs are too expensive to cover for all members for whom they would be prescribed (38%) and considering these to be lifestyle drugs which are excluded from coverage (27%)